Clinical Trial Update: PULSAR Combined With PD-1 Ab and Chemotherapy Plus Bev. for CRLM [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating PULSAR in combination with a PD-1 inhibitor, chemotherapy, and bevacizumab for colorectal cancer with liver metastases; t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer with Liver Metastases

Drugs mentioned

• Bevacizumab (bevacizumab)
• PD-1 inhibitor
• PULSAR

Snippet

Sponsor: Fujian Cancer Hospital | Conditions: Colorectal Cancer Liver Metastasis | Phase 2 | Status: NOT_YET_RECRUITING